Pengaruh Pemberian Tepung Magot (Hermetia Illucens) Dalam Pakan Buatan Terhadap Pertumbuhan, Efisiensi Pakan Dan Kelangsungan Hidup Benih Ikan Mas (Cyprinus Carpio L.) [the Feeding Effect of Maggot Meal (Hermetia Illucens) in Artificial Feed on Growth, Feed Efficiency and Survival Rate of Common Carp Juvenile (Cyprinus Carpio L.) ]

Carp (C. carpio L.) is one commodity of fresh water fishery sector continues to grow rapidly in Indonesia. One of the factors that determine the success of aquaculture is the availability of sufficient feed, both in quantity and quality. The aim of this research was to find out optimum percentage of feeding maggot meal in artificial feed on growth, efficiency of feed and survival rate of common carp juvenile. The treatment of this researh was feeding maggot meal in artificial feed i.e. 0%, 5%, 10%, 15%, and 20%. The design of this research was Completely Randomized Design. Data analysis used Analysis of Variance (ANOVA) to know the effect of the treatment and the difference among the treatment used Duncan's Multiple Range Test (DMRT). The result of this research showed that the growth, efficiency of feed and survival rate of common carp that given maggot meal in artificial feed was not significantly (P>0,05). Water quality on culture medium, temperature, pH, dissolved oxygen, and ammonia was 2832oC, 7-8, 5 mg/L and 0,02-0,05mg/L respectively

AR101 Oral Immunotherapy for Peanut Allergy

BACKGROUND Peanut allergy, for which there are no approved treatment options, affects patients who are at risk for unpredictable and occasionally life-threatening allergic reactions. METHODS In a phase 3 trial, we screened participants 4 to 55 years of age with peanut allergy for allergic dose-limiting symptoms at a challenge dose of 100 mg or less of peanut protein (approximately one third of a peanut kernel) in a double-blind, placebo-controlled food challenge. Participants with an allergic response were randomly assigned, in a 3:1 ratio, to receive AR101 (a peanut-derived investigational biologic oral immunotherapy drug) or placebo in an escalating-dose program. Participants who completed the regimen (i.e., received 300 mg per day of the maintenance regimen for approximately 24 weeks) underwent a double-blind, placebo-controlled food challenge at trial exit. The primary efficacy end point was the proportion of participants 4 to 17 years of age who could ingest a challenge dose of 600 mg or more, without dose-limiting symptoms. RESULTS Of the 551 participants who received AR101 or placebo, 496 were 4 to 17 years of age; of these, 250 of 372 participants (67.2%) who received active treatment, as compared with 5 of 124 participants (4.0%) who received placebo, were able to ingest a dose of 600 mg or more of peanut protein, without dose-limiting symptoms, at the exit food challenge (difference, 63.2 percentage points; 95% confidence interval, 53.0 to 73.3; P CONCLUSIONS In this phase 3 trial of oral immunotherapy in children and adolescents who were highly allergic to peanut, treatment with AR101 resulted in higher doses of peanut protein that could be ingested without dose-limiting symptoms and in lower symptom severity during peanut exposure at the exit food challenge than placebo